BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16291426)

  • 1. Pemetrexed: a new cytotoxic agent in the development for first-line non-small-cell lung cancer.
    Scagliotti GV
    Lung Cancer; 2005 Oct; 50 Suppl 1():S18-9. PubMed ID: 16291426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trials of pemetrexed.
    Fossella FV; Gatzemeier U
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy.
    Molina JR; Adjei AA
    Clin Lung Cancer; 2003 Jul; 5(1):21-7. PubMed ID: 14596699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed for treatment of advanced non-small cell lung cancer.
    Fossella FV
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):100-5. PubMed ID: 14981587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer.
    Tucker S
    Curr Drug Targets; 2010 Jan; 11(1):58-60. PubMed ID: 19839927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed in the treatment of non-small cell lung cancer.
    Shepherd FA
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):43-8. PubMed ID: 12571810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed as a single agent in the therapy of advanced lung cancer.
    Postmus PE; Bunn PA
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):17-22. PubMed ID: 12023788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed in the treatment of advanced non-squamous lung cancer.
    Rossi A; Ricciardi S; Maione P; de Marinis F; Gridelli C
    Lung Cancer; 2009 Nov; 66(2):141-9. PubMed ID: 19577816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seeking new options for the treatment of small-cell lung cancer.
    Socinski MA
    Lung Cancer; 2005 Oct; 50 Suppl 1():S25-6. PubMed ID: 16291430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimetabolites in the management of non-small cell lung cancer.
    Budde LS; Hanna NH
    Curr Treat Options Oncol; 2005 Jan; 6(1):83-93. PubMed ID: 15610718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
    Le Chevalier T
    Semin Oncol; 2003 Aug; 30(4 Suppl 10):37-44. PubMed ID: 12947960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
    Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the treatment of second-line non-small-cell lung cancer.
    Hanna N
    Lung Cancer; 2005 Oct; 50 Suppl 1():S15-7. PubMed ID: 16291425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.
    Cullen MH; Zatloukal P; Sörenson S; Novello S; Fischer JR; Joy AA; Zereu M; Peterson P; Visseren-Grul CM; Iscoe N
    Ann Oncol; 2008 May; 19(5):939-45. PubMed ID: 18283036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
    Suwanrusme H; Meyer ML; Green MR
    Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S56-60. PubMed ID: 15117426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.